The proapoA-I mutants of the present invention exhibit superior
LDL-antioxidant activities over the wild-type proapoA-I and higher
efficiencies for delivering cholesterol to hepatocytes than the
previously reported apoA-I-R173C, and thus they can be effectively used
for prevention and treatment of hyperlipidemia or atherosclerosis.